Preclinical studies showed that BCL-2 is overexpressed in high-risk MDS, and its inhibition induces apoptosis in MDS progenitor cells (Jilg et al., 2016; Parker et al., 2000). The gene discussed is BCL2; the disease is myelodysplastic syndrome.